Literature DB >> 2141495

Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone.

A Jackson1, J H Scarffe.   

Abstract

In a prospective study of 32 patients with solitary myeloma of bone treated between 1974 and 1984, the median survival was 117 months. Twenty of the patients developed multiple myeloma with a median time to dissemination of 46 months. A multivariate analysis of presenting prognostic factors identified osteopenia (P less than 0.000003) and immunoparesis (P less than 0.00002) as the only independent prognosticators of overall survival. The removal of patients with osteopenia or immunoparesis at presentation identified a group of patients with 80-90% chance of surviving 10 years. Patients with either of the risk factors have a median survival of 27 months similar to patients with multiple myeloma, and should be considered for early systemic treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141495     DOI: 10.1016/0277-5379(90)90235-l

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Mini review: surgical management of primary chest wall tumors.

Authors:  Takamasa Ito; Hidemi Suzuki; Ichiro Yoshino
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-10-24

Review 2.  Total spondylectomy for solitary bone plasmacytoma of the lumbar spine in a young woman: a case report and review of literature.

Authors:  Nicolas H von der Hoeh; Sven Kevin Tschoeke; Jens Gulow; Anna Voelker; Udo Siebolts; Christoph-Eckhard Heyde
Journal:  Eur Spine J       Date:  2013-08-30       Impact factor: 3.134

3.  Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004.

Authors:  Graça M Dores; Ola Landgren; Katherine A McGlynn; Rochelle E Curtis; Martha S Linet; Susan S Devesa
Journal:  Br J Haematol       Date:  2008-11-11       Impact factor: 6.998

4.  Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; F K Buadi; M Q Lacy; S Zeldenrust; S R Hayman; N Leung; T V Kourelis; W Gonsalves; R Chakraborty; S Russell; D Dingli; J A Lust; Y Lin; P Kapoor; R Go; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

5.  Solitary plasmacytoma of the rib: A rare case.

Authors:  Rikki Singal; Usha Dalal; Ashwani Kumar Dalal; Ashok Kumar Attri; Samita Gupta; Rachna Raina
Journal:  Lung India       Date:  2011-10

Review 6.  Surgery combined with radiotherapy for the treatment of solitary plasmacytoma of the rib: a case report and review of the literature.

Authors:  Rui Jia; Lei Xue; Huagang Liang; Kun Gao; Jian Li; Zhefeng Zhang
Journal:  J Cardiothorac Surg       Date:  2015-10-13       Impact factor: 1.637

7.  [Solitary bone plasmacytoma: experience of the National Institute of Oncology, Rabat (INO)].

Authors:  Adama Diakité; Karima Nouni; Sara Bellefqih; Tayeb Kebdani; Noureddine Benjaafar
Journal:  Pan Afr Med J       Date:  2014-03-07

8.  Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone.

Authors:  L Y Shih; P Dunn; W M Leung; W J Chen; P N Wang
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.